MENU
THNR
ETF ticker: NYSE ARCA
PRICE
CHANGE
NET ASSETS

THNR stock forecast, quote, news & analysis

The investment seeks investment results that generally correspond to the performance of the VettaFi Weight Loss Drug & Treatment Index... Show more

Category: #Health
THNR
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for THNR with price predictions
Jul 13, 2026

THNR's RSI Indicator leaves overbought zone

The 10-day RSI Oscillator for THNR moved out of overbought territory on July 08, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 9 instances where the indicator moved out of the overbought zone. In of the 9 cases the stock moved lower in the days that followed. This puts the odds of a move down at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 25 cases where THNR's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where THNR declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

THNR broke above its upper Bollinger Band on July 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on June 22, 2026. You may want to consider a long position or call options on THNR as a result. In of 28 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for THNR just turned positive on June 12, 2026. Looking at past instances where THNR's MACD turned positive, the stock continued to rise in of 19 cases over the following month. The odds of a continued upward trend are .

THNR moved above its 50-day moving average on June 23, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for THNR crossed bullishly above the 50-day moving average on June 26, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 7 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

The 50-day moving average for THNR moved above the 200-day moving average on July 08, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where THNR advanced for three days, in of 116 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 84 cases where THNR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Merck & Co (NYSE:MRK), AstraZeneca PLC (NYSE:AZN), Amgen (NASDAQ:AMGN), Pfizer (NYSE:PFE), Teva Pharmaceutical Industries Limited (NYSE:TEVA).

Industry description

The investment seeks investment results that generally correspond to the performance of the VettaFi Weight Loss Drug & Treatment Index. The fund's manager invests at least 80% of its net assets (plus borrowings for investment purposes) in securities that comprise the index. The index is comprised of global companies expected to economically benefit from weight loss drug development. The index includes pharmaceutical manufacturers, manufacturers of combination therapies and telehealth providers who provide access to Amylin agonists and analogs or GLP-1 agonists and analogs, including dual GLP-1 agonists and analogs. The fund is non-diversified.

Market Cap

The average market capitalization across the Amplify Weight Loss Drug & Treatment ETF ETF is 163.6B. The market cap for tickers in the group ranges from 581.48M to 1.05T. LLY holds the highest valuation in this group at 1.05T. The lowest valued company is ALT at 581.48M.

High and low price notable news

The average weekly price growth across all stocks in the Amplify Weight Loss Drug & Treatment ETF ETF was -3%. For the same ETF, the average monthly price growth was 5%, and the average quarterly price growth was -2%. PFE experienced the highest price growth at 3%, while OPK experienced the biggest fall at -18%.

Volume

The average weekly volume growth across all stocks in the Amplify Weight Loss Drug & Treatment ETF ETF was -25%. For the same stocks of the ETF, the average monthly volume growth was -21% and the average quarterly volume growth was -38%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 42
P/E Growth Rating: 65
Price Growth Rating: 38
SMR Rating: 62
Profit Risk Rating: 68
Seasonality Score: -4 (-100 ... +100)
View a ticker or compare two or three
THNR
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Health

Profile
Details
THNR's RSI Indicator leaves overbought zone